Complications of targeted drug therapies for solid malignancies: Manifestations and mechanisms

Richard G. Abramson*, Vandana G. Abramson, Emily Chan, Leora Horn, Vicki L. Keedy, William Pao, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


OBJECTIVE. This article reviews important complications of targeted drug therapies for solid malignancies that can be identified on diagnostic imaging. Wherever possible, known or proposed mechanistic explanations for drug complications are emphasized. CONCLUSION. Familiarity with the toxicity profiles of different targeted cancer therapies is important for identifying drug-related complications and for differentiating drug effects from disease progression. A mechanistic understanding may be useful for associating individual drugs with their complications and for predicting the complications of emerging agents.

Original languageEnglish (US)
Pages (from-to)475-483
Number of pages9
JournalAmerican Journal of Roentgenology
Issue number3
StatePublished - Mar 2013


  • Bevacizumab
  • Drug toxicities
  • Imatinib
  • Ipilimumab
  • Targeted agents
  • Temsirolimus
  • Vemurafenib

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Complications of targeted drug therapies for solid malignancies: Manifestations and mechanisms'. Together they form a unique fingerprint.

Cite this